Policy · 117th Congress
House report questions FDA’s approval of Alzheimer’s drug
A decision on accelerated approval is due by Jan. 6, and the company is simultaneously submitting data for full approval based on results from a Phase 3 trial.
Search Roll Call
Search the Roll Call archive by keyword, date, Congress, section, or tags.
5 results for "6"
Policy · 117th Congress
Biden ponders marijuana moves as states forge ahead
The Biden administration’s Oct. 6 announcement that it would revisit that classification comes after previous, yearslong reviews of marijuana’s categorization fell flat, and experts are split on
Policy · 117th Congress
Medicare demo emerges as coverage option for Alzheimer’s drug
Alzheimer’s afflicts more than 6 million Americans, and is the sixth-leading cause of death in the United States.
Opinion · 117th Congress
We can’t wait for the pandemic to end to fight the opioid overdose surge
Joe Manchin III, D-W.Va., to more effectively confront one of the biggest drivers in the overdose spike — illicitly manufactured fentanyl — and address a looming deadline on May 6.
Opinion · 117th Congress
Companies are abandoning anti-democratic politicians, but they shouldn’t abandon their PACs
In the wake of the events of Jan. 6, about 50 companies have now announced they are banning contributions to the 147 legislators in question or taking a pause from making PAC donations or, in a few